Summary
The distribution and density of3H-MPP+ binding sites were studied by in vitro quantitative autoradiography in the brain of the mouse, rat and monkey. The highest levels of3H-MPP+ specific binding were observed in rat brain. The substantia nigra in rat and monkey, and the anterior caudate-putamen formation in mouse and monkey showed the lowest density of autoradiographic grains. The presence of a relatively high density of MPP+ sites in the hippocampus of all species studied could be of interest to explain some effects of MPTP administration on convulsions caused by chemoconvulsants.
The finding of a 60–70% reduction of3H-MPP+ binding sites in the rat caudate-putamen, on the side of quinolinic acid infusion and no changes after 6-hydroxydopamine lesion of dopaminergic nigrostriatal neurons suggests the presence of these sites mainly on striatal cells.
The results suggest that the distribution of MPP+ binding sites in brain would not seem to be related to MPTP toxicity.
Similar content being viewed by others
References
Bjorklund A, Lindvall O (1984) Dopamine-containing systems in the CNS. In: Bjorklund A, Hokfelt T (eds) Handbook of chemical neuroanatomy, vol 2, part I. Elsevier, Amsterdam, pp 55–122
Bocchetta A, Piccardi MP, Del Zompo M, Pintus S, Corsini GU (1985) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro. J Neurochem 5: 673–676
Bradbury AJ, Costall B, Domeney AM, Jenner PJ, Marsden CD, Naylor RJ (1986) 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 319: 56–57
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550
Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578
Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ (1984) Selective neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in subhuman primates and man: a new animal model of parkinson's disease. Psychopharmacol Bull 20: 548–553
Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209–210
D'Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987–989
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Riechert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res 1: 249–254
Del Zompo M, Bernardi F, Maggio R, Piccardi MP, Johannessen JN, Corsini GU (1986a) High affinity binding sites for 1-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. Eur J Pharm 129: 87–92
Del Zompo M, Piccardi MP, Bernardi F, Bonuccelli U, Corsini GU (1986b) Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies. Brain Res 378: 320–324
Del Zompo M, Ruiu S, Maggio R, Piccardi MP, Corsini GU (1990)3H-MPP+ binding sites in mouse brain: pharmacological and biological characterization. J Neurochem 54: 1905–1910
Fariello RG, De Mattei M, Castorina M, Ferraro TN, Golden GT (1987) MPTP and convulsive responses in rodents. Brain Res 426: 373–376
Fuller RW, Hemrick-Luecke SK (1985) Influence of selective reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Life Sci 37: 1089–1096
Heikkila RE, Manzino, L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by monoamino oxidase inhibitors. Nature 311: 467–469
Herkenham M, Little MD, Bankiewicz K, Yang S-C, Markey SP, Johannessen JN (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40: 133–158
Hokfelt T, Johanson O, Goldstein M (1984) Chemical anatomy of the brain. Science 225: 1326–1334
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177
Javoy F, Sotelo C, Herbet A, Agid Y (1976) Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res 102: 201–215
Jonsson G (1983) Chemical lesioning techniques: monoamine neurotoxins. In: Bjorklund A, Hokfelt T (eds) Handbook of chemical neuroanatomy. Methods in chemical neuroanatomy, vol. 1. Elsevier, Amsterdam, pp 466–477
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464–467
Namura I, Douillet P, Sun J, Pert A, Cohen RM, Chiueh CC (1987) MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-norepinephrine- and serotonin-containing neurons. Eur J Pharmacol 136: 31–37
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, New York
Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) Stereotaxic atlas of the rat brain. Plenum Press, New York
Rainbow TC, Parsons B, Wieczorek CM, Manaker S (1985) Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with3H-pargyline binding to monoamine oxidase. Brain Res 330: 337–342
Scatton B, Dubois A, Dubocovich ML, Zahniser NR, Fage D (1985) Quantitative autoradiography of3H-nomifensine binding sites in rat brain. Life Sci 36: 815–822
Scatton B, Dubois A, Camus A, Zahniser NR, Dubocovich ML, Agid Y, Cudennec A (1986) Autoradiographic visualization and quantification of dopamine receptors and uptake sites in the rat and human CNS. In: Woodruff GN, et al (eds) Dopaminergic systems and their regulation. Macmillan Press, London, pp 111–130
Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesion in rat brain. Science 219: 316
Slotnick BM, Leonard CM (1975) A stereotaxic atlas of the albino mouse forebrain. US Department of Health, Education and Welfare, Rockville MD
Stephan H, Baron G, Schwerdtfeger WK (1980) The brain of the common marmoset (callithrix jacchus). Springer, Berlin Heidelberg New York
Sun CJ, Johannessen JN, Gessner W, Namura I, Singhaniyom W, Brossi A, Chiueh CC (1988) Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+. J Neural Transm 74: 75–86
Tassin JP, Chéramy A, Blanc G, Thierry AM, Glowinski J (1976) Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. I. Microestimation of3H-dopamine uptake and dopamine content in microdiscs Brain Res 107: 291–301
Van Ness PC, Olsen RW, Verity MA (1989) MPTP is proconvulsant acutely but has no long-term effect in rodent models of seizure and epilepsy. Brain Res 504: 289–292
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Zompo, M., Piccardi, M.P., Ruiu, S. et al. Localization of MPP+ binding sites in the brain of various mammalian species. J Neural Transm Gen Sect 4, 181–190 (1992). https://doi.org/10.1007/BF02260902
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260902